North America
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology Congress
Princeton, NJ and TOKYO, September 11, 2025- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET-SHUTTLE trial of rocatinlimab, an investigational T-cell rebalancing therapy, will be presented as a late breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) 2025 Annual Meeting to be held in Paris, France from September 17-20, 2025. This trial assessed the efficacy and safety of rocatinlimab every 4 weeks in combination with topical corticosteroids and/or topical calcineurin inhibitors in adults with moderate-to-severe atopic dermatitis (AD).
Moderate-to-severe AD is a chronic inflammatory skin disease that can cause severe itching and pain. Despite available treatment options, there remains a significant unmet need as some patients with moderate to severe AD fail to achieve or sustain treatment goals.
Title: Rocatinlimab with Concomitant Topical Therapy Significantly Impro
11 September 2025
